Which is more profitable, Eli Lilly or UCB SA?

Eli Lilly keeps more of every sale as profit.

Which grows faster, Eli Lilly or UCB SA?

Eli Lilly grew its sales faster in recent years.

Which is cheaper, Eli Lilly or UCB SA?

UCB SA costs less for each unit of yearly profit (lower P/E).

Which has less debt, Eli Lilly or UCB SA?

UCB SA would need fewer years of earnings to pay off its debt.

Eli LillyLLYvs

UCB SAUCB.BR

Eli Lilly vs UCB SA stock

Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.

In one sentence

Eli Lilly is more profitable and grows faster. UCB SA is cheaper for its profits and has less debt.

Side by side

	Eli Lilly	UCB SA
	$1.29 trillion	€56.5 billion
	31.7%	20.1%
	+21.6%	+12.0%
	62.3×	36.3×
	1.1 years	Net cash
	34.8%	11.2%
	0.6%	0.5%

Open Eli Lilly Open UCB SA

How we compare

Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.

More comparisons: Eli Lilly vs UnitedHealth · Eli Lilly vs Vertex Pharmaceuticals · Eli Lilly vs AbbVie · Eli Lilly vs Abbott Laboratories · UCB SA vs Roche · UCB SA vs UnitedHealth · UCB SA vs AbbVie · UCB SA vs Johnson & Johnson